Difference between revisions of "Brentuximab vedotin (Adcetris)"
Jump to navigation
Jump to search
m (Text replace - "or the prescribing information<ref name="insert"></ref>." to "or the prescribing information.<ref name="insert"></ref>") |
(updated content) |
||
| Line 1: | Line 1: | ||
| − | + | '''FDA approved 8/19/2011'''. Also known as SGN-35 and cAC10-vcMMAE. | |
==General information== | ==General information== | ||
| − | Class/mechanism: Anti-CD30 antibody (brentuximab) with protease-cleavable linker to chemotherapeutic agent (monomethyl auristatin E (MMAE, vedotin)). The antibody-drug complex binds to CD30 expressing cells and is internalized, where the active chemotherapeutic agent MMAE is released via proteolytic cleavage of the antibody-drug linker. MMAE is a microtubule disrupting agent that interferes with mitosis, causes cell cycle arrest, and eventual apoptosis.<ref name="insert">[http://www.adcetris.com/_pdf/Final_Adcetris_USPI_Jan12_2012.pdf Brentuximab vedotin (Adcetris) package insert]</ref><ref>[ | + | Class/mechanism: Anti-CD30 antibody (brentuximab) with protease-cleavable linker to chemotherapeutic agent (monomethyl auristatin E (MMAE, vedotin)). The antibody-drug complex binds to CD30 expressing cells and is internalized, where the active chemotherapeutic agent MMAE is released via proteolytic cleavage of the antibody-drug linker. MMAE is a microtubule disrupting agent that interferes with mitosis, causes cell cycle arrest, and eventual apoptosis.<ref name="insert">[http://www.adcetris.com/_pdf/Final_Adcetris_USPI_Jan12_2012.pdf Brentuximab vedotin (Adcetris) package insert]</ref><ref>[[Media:Brentuximabvedotin.pdf | Brentuximab vedotin (Adcetris) package insert (locally hosted backup)]]</ref><ref>[http://www.adcetris.com Adcetris manufacturer's website]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[Hodgkin lymphoma]] | ||
==Patient drug information== | ==Patient drug information== | ||
| + | *[http://chemocare.com/chemotherapy/drug-info/brentuximab-vedotin.aspx Brentuximab vedotin (Adcetris) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/brentuximab-vedotin.aspx Brentuximab vedotin (Adcetris) patient drug information (Chemocare)]</ref> | ||
| + | *Brief patient counseling information can be found on [http://www.adcetris.com/_pdf/Final_Adcetris_USPI_Jan12_2012.pdf#page=15 page 15 of the package insert]<ref name="insert"></ref> | ||
*[http://www.uptodate.com/contents/brentuximab-vedotin-patient-drug-information Brentuximab vedotin (Adcetris) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/brentuximab-vedotin-patient-drug-information Brentuximab vedotin (Adcetris) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/brentuximab-vedotin-patient-drug-information Brentuximab vedotin (Adcetris) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/brentuximab-vedotin-patient-drug-information Brentuximab vedotin (Adcetris) patient drug information (UpToDate)]</ref> | ||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 20:12, 7 October 2012
FDA approved 8/19/2011. Also known as SGN-35 and cAC10-vcMMAE.
General information
Class/mechanism: Anti-CD30 antibody (brentuximab) with protease-cleavable linker to chemotherapeutic agent (monomethyl auristatin E (MMAE, vedotin)). The antibody-drug complex binds to CD30 expressing cells and is internalized, where the active chemotherapeutic agent MMAE is released via proteolytic cleavage of the antibody-drug linker. MMAE is a microtubule disrupting agent that interferes with mitosis, causes cell cycle arrest, and eventual apoptosis.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Brentuximab vedotin (Adcetris) patient drug information (Chemocare)[4]
- Brief patient counseling information can be found on page 15 of the package insert[1]
- Brentuximab vedotin (Adcetris) patient drug information (UpToDate)[5]
References
- ↑ 1.0 1.1 1.2 Brentuximab vedotin (Adcetris) package insert
- ↑ Brentuximab vedotin (Adcetris) package insert (locally hosted backup)
- ↑ Adcetris manufacturer's website
- ↑ Brentuximab vedotin (Adcetris) patient drug information (Chemocare)
- ↑ Brentuximab vedotin (Adcetris) patient drug information (UpToDate)